A leading global health advocacy organization needed a strategic plan to focus its activities and communicate its objectives more effectively to donors, partners and advocacy targets. The organization retained Dalberg to identify and prioritize the most critical gaps in the advocacy environment.Dalberg Approach
Dalberg assessed the organization's efforts, capabilities, and operating environment to target the most urgent issues where it could be effective. The team worked with the client to define strategic objectives and an impact plan that could be easily understood by its stakeholders. Finally, Dalberg developed a new organizational structure, criteria for engaging in new issues, and a funding strategy for the plan.Results
The strategic plan won positive feedback from staff, partners, and donors with one donor subsequently giving the organization more funding than requested. Internally, the organization gained a more accountability-focused approach that underpinned its expansion into Europe and Africa.To learn more about our Global Health practice area, click here.
The pharmaceutical industry has been challenged by its employees and external stakeholders to address diseases in poor countries, which are otherwise neglected by the market. An industry taskforce retained Dalberg to assess the feasibility of a joint fund to finance R&D on these diseases which might otherwise never be addressed.Dalberg Approach
Dalberg analyzed market needs and developing the criteria for an effective fund. Dalberg identified key barriers to its establishment and developed options and recommendations for the scope, structure and financing for the fund. Dalberg engaged key stakeholders to understand their priorities and the potential barriers to success.Results
The task force accepted the recommended design for a fund to bring multiple sectors together in order to improve the availability of medicines in these areas. The task force is now mobilizing stakeholders around the proposed fund mechanism.To learn more about our Global Health practice area, click here.
Artemisinin-based combination therapies (ACTs) are a highly effective treatment for malaria that has not reached large parts of the global population because of cost and distributional challenges. Leading economists and global health experts recommended a new financing mechanism for ACTs, and Dalberg was employed to develop it.Dalberg Approach
Dalberg was commissioned by the World Bank to design an affordable medicines facility (or fund) that would lower the price of ACTs and encourage outlets that serve vulnerable populations to stock them. Engaging pivotal stakeholders in global health, Dalberg designed a demand-driven structure accessible to public and private distributors of malaria medicines.Results
In 2007, the Roll Back Malaria (RBM) Partnership approved the design for the Affordable Medicines Facility - malaria (AMFm). The mechanism, now managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria, raises more than $200m for ACTs each year.To learn more about our Global Health practice area, click here.